文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

糖皮质激素治疗与机械通气COVID-19相关ARDS患者死亡率:一项多中心队列研究

Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study.
PubMed 文献 · Ann Intensive Care · 2021-11-26
一句话结论机械通气COVID-19相关ARDS患者接受糖皮质激素治疗对ICU死亡率呈双相时间依赖性效应:短期生存获益(HR 0.53),17天后转为死亡风险增加(长期HR 1.68)。

这项回顾性研究基于70个ICU前瞻性收集的数据,纳入2020年2月6日至9月20日期间1835例机械通气COVID-19相关ARDS患者,其中1117例(60.9%)接受糖皮质激素。倾向评分匹配后,糖皮质激素组与未治疗组ICU死亡率无显著差异(33.8% vs. 30.9%;p=0.28)。生存分析显示,入ICU时使用糖皮质激素与短期生存获益相关(HR 0.53;95%CI 0.39-0.72),但入住17天后效应反转,长期ICU死亡率增加(HR 1.68;95%CI 1.16-2.45)。年龄<60岁、重度ARDS及糖皮质激素联合托珠单抗亚组可能获益最大。

要点

  • 倾向评分匹配后,糖皮质激素组与未治疗组ICU死亡率无显著差异(33.8% vs. 30.9%;p=0.28)。
  • 入ICU时使用糖皮质激素与短期生存获益相关(HR 0.53;95%CI 0.39-0.72),但入住17天后效应反转,长期ICU死亡率增加(HR 1.68;95%CI 1.16-2.45)。
  • 年龄<60岁、重度ARDS及糖皮质激素联合托珠单抗亚组可能从糖皮质激素中获得最大短期生存获益且无长期负面影响。
  • 在ICU和非幸存者中,糖皮质激素组住院时间更长;其余次要结局无显著差异。
  • 作者认为需进一步研究以识别机械通气COVID-19相关ARDS患者中对糖皮质激素治疗有反应的亚组。

适用人群与场景

  • 纳入:2020年2月6日至9月20日期间入住70个ICU(68个西班牙、1个安道尔、1个爱尔兰)的机械通气COVID-19相关ARDS患者。
  • 排除:因难治性休克接受糖皮质激素的患者。

研究设计与关键结果

  • 研究类型:回顾性研究,基于前瞻性收集的数据,在70个ICU进行,纳入1835例机械通气COVID-19相关ARDS患者,其中1117例(60.9%)接受糖皮质激素。
  • 主要终点:倾向评分匹配后,糖皮质激素组与未治疗组ICU死亡率无显著差异(33.8% vs. 30.9%;p=0.28)。
  • 生存分析:入ICU时使用糖皮质激素与短期生存获益相关(HR 0.53;95%CI 0.39-0.72);入住17天后效应反转,长期ICU死亡率增加(HR 1.68;95%CI 1.16-2.45)。
  • 亚组:年龄<60岁、重度ARDS及糖皮质激素联合托珠单抗亚组可能从糖皮质激素中获得最大短期生存获益且无长期负面影响。
  • 次要终点:在ICU和非幸存者中,糖皮质激素组住院时间更长;其余次要结局无显著差异。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究(基于前瞻性收集的数据)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对机械通气COVID-19相关ARDS患者,糖皮质激素治疗对ICU死亡率呈双相时间依赖性效应,特定亚组(年龄<60岁、重度ARDS、糖皮质激素联合托珠单抗)显示明确的生存改善。
  • 作者建议,需进一步研究以识别机械通气COVID-19相关ARDS患者中对糖皮质激素治疗有反应的亚组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Some unanswered questions persist regarding the effectiveness of corticosteroids for severe coronavirus disease 2019 (COVID-19) patients. We aimed to assess the clinical effect of corticosteroids on intensive care unit (ICU) mortality among mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients.

METHODS: This was a retrospective study of prospectively collected data conducted in 70 ICUs (68 Spanish, one Andorran, one Irish), including mechanically ventilated COVID-19-associated ARDS patients admitted between February 6 and September 20, 2020. Individuals who received corticosteroids for refractory shock were excluded. Patients exposed to corticosteroids at admission were matched with patients without corticosteroids through propensity score matching. Primary outcome was all-cause ICU mortality. Secondary outcomes were to compare in-hospital mortality, ventilator-free days at 28 days, respiratory superinfection and length of stay between patients with corticosteroids and those without corticosteroids. We performed survival analysis accounting for competing risks and subgroup sensitivity analysis.

RESULTS: We included 1835 mechanically ventilated COVID-19-associated ARDS, of whom 1117 (60.9%) received corticosteroids. After propensity score matching, ICU mortality did not differ between patients treated with corticosteroids and untreated patients (33.8% vs. 30.9%; p = 0.28). In survival analysis, corticosteroid treatment at ICU admission was associated with short-term survival benefit (HR 0.53; 95% CI 0.39-0.72), although beyond the 17th day of admission, this effect switched and there was an increased ICU mortality (long-term HR 1.68; 95% CI 1.16-2.45). The sensitivity analysis reinforced the results. Subgroups of age < 60 years, severe ARDS and corticosteroids plus tocilizumab could have greatest benefit from corticosteroids as short-term decreased ICU mortality without long-term negative effects were observed. Larger length of stay was observed with corticosteroids among non-survivors both in the ICU and in hospital. There were no significant differences for the remaining secondary outcomes.

CONCLUSIONS: Our results suggest that corticosteroid treatment for mechanically ventilated COVID-19-associated ARDS had a biphasic time-dependent effect on ICU mortality. Specific subgroups showed clear effect on improving survival with corticosteroid use. Therefore, further research is required to identify treatment-responsive subgroups among the mechanically ventilated COVID-19-associated ARDS patients.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Moreno G, Carbonell R, Martin-Loeches I, et al. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Ann Intensive Care. 2021. PMID: 34825976. doi:10.1186/s13613-021-00951-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。